Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$9.16 -0.15 (-1.61%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$9.15 -0.01 (-0.11%)
As of 05/23/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$8.85
$9.71
50-Day Range
$6.07
$10.15
52-Week Range
$5.14
$29.46
Volume
284,858 shs
Average Volume
327,321 shs
Market Capitalization
$492.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 691st out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Upstream Bio has received no research coverage in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Short Interest

    There is no current short interest data available for UPB.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for UPB.
  • News Sentiment

    Upstream Bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Upstream Bio this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

UPB Stock News Headlines

Upstream Bio Appoints Stacy Price As CTO
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB shares have decreased by 44.3% and is now trading at $9.16.
View the best growth stocks for 2025 here
.

Upstream Bio, Inc. (NASDAQ:UPB) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.02. The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.71 million.

Upstream Bio (UPB) raised $200 million in an initial public offering on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Upstream Bio's lock-up period expired on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Since the end of Upstream Bio's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Upstream Bio's top institutional shareholders include Wellington Management Group LLP (2.44%), Siren L.L.C. (1.47%), Siren L.L.C. (1.47%) and Nantahala Capital Management LLC (1.11%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/06/2025
Today
5/24/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.50
High Stock Price Target
$75.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+516.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$492.75 million
Optionable
N/A
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners